Tekin Selin Balki, Kenar Ayşe Nur İnci
Clinic of Psychiatry, Denizli State Hospital, Denizli, Türkiye.
Department of Psychiatry, Pamukkale University Faculty of Medicine, Denizli, Türkiye.
Psychiatry Clin Psychopharmacol. 2025 Jun 25;35(3):311-314. doi: 10.5152/pcp.2025.251123.
The comorbidity of schizophrenia and obsessive-compulsive disorder (OCD) has been demonstrated to result in more severe symptoms and a worse prognosis for patients, as well as a more challenging treatment process for clinicians. Lurasidone is a second-generation atypical antipsychotic approved for the treatment of schizophrenia. This case report aims to share the use and treatment process of lurasidone in a 28-year-old male patient with a history of OCD and schizophrenia since childhood. The patient has had multiple hospitalizations and suicide attempts and has received ECT (electroconvulsive therapy) and TMS (transcranial magnetic stimulation) treatment on numerous occasions. The patient has been resistant to various drug treatments, including clozapine. Following the administration of lurasidone at a dosage of 80 mg/day and above, the patient exhibited a regression in their psychotic symptoms, depressive and obsessive complaints, and demonstrated a substantial enhancement in social and cognitive functioning. No adverse effects related to lurasidone were reported. These findings suggest that lurasidone may be a safe treatment option for schizophrenia and comorbid disorders. Its receptor profile suggests many advantageous features in terms of both treatment and side effect tolerability, and it provides a significant improvement in functionality.
精神分裂症与强迫症（OCD）的共病已被证明会导致患者症状更严重、预后更差，同时也给临床医生的治疗过程带来更大挑战。鲁拉西酮是一种被批准用于治疗精神分裂症的第二代非典型抗精神病药物。本病例报告旨在分享鲁拉西酮在一名自童年起就患有强迫症和精神分裂症病史的28岁男性患者中的使用及治疗过程。该患者曾多次住院并尝试自杀，还多次接受过电休克治疗（ECT）和经颅磁刺激（TMS）治疗。患者对包括氯氮平在内的各种药物治疗均有耐药性。在给予鲁拉西酮每日80毫克及以上剂量后，患者的精神病症状、抑郁和强迫症状有所缓解，社会和认知功能有显著改善。未报告与鲁拉西酮相关的不良反应。这些发现表明，鲁拉西酮可能是治疗精神分裂症及其共病的一种安全选择。其受体特征表明，在治疗和副作用耐受性方面具有许多优势，并且能显著改善功能。
